December 11, 2013
HealthDay News — About three-quarters of opioid-dependent patients who participated in anonymous surveys and interviews indicated a preference for oxycodone or hydrocodone, researchers have found.
Significantly more users chose oxycodone than hydrocodone — 44.7% vs. 29.4% — mainly because of perceived superior quality, Theodore J. Cicero, PhD, from Washington University in St. Louis, and colleagues reported in PAIN.
They conducted anonymous (more…)
Signature Therapeutics, Inc. (PRNewsFoto/Signature Therapeutics, Inc.)
PALO ALTO, Calif., July 29, 2013 /PRNewswire/ — Signature Therapeutics, Inc., a development-stage biopharmaceutical company, announced today that it has received no-cost access to contractor resources through the National Center for Advancing Translational Sciences’ Bridging Interventional Development Gaps (BrIDGs) program (part of the NIH) to support development of its extended-release, abuse-deterrent oxycodone, PF614 – (more…)
Intellipharmaceutics International Inc. (Nasdaq: IPCI), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced an update on the following events in its Rexista™ oxycodone development program:
1) The results of the current stage of development and physico-chemical tests to assess abuse-deterrent properties of its Rexista™ oxycodone
2) Stability studies